This year, Gavi will renegotiate the price it pays for the PCV vaccine from Pfizer and GSK. Eight years ago Gavi negotiated the lowest price ever secured for the world’s poorest countries through a special financing mechanism called the Advance Market Commitment (AMC) for Pneumococcal Conjugate Vaccines. The expectation was that the price would be significantly reduced as years passed to make this vaccine more affordable for developing countries. But while in those 8 years the companies made more than US$36 billion on global sales of PCV vaccines, they only reduced the price by 11 % (Pfizer) and 13% (GSK) for the poorest countries. PCV remains one of the most expensive vaccines for developing countries to date.